Compare · BDX vs TMO
BDX vs TMO
Side-by-side comparison of Becton Dickinson and Company (BDX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- BDX operates in Health Care, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $255.19B, about 4.4x BDX ($57.93B).
- Over the past year, BDX is up 42.8% and TMO is up 20.3% - BDX leads by 22.6 points.
- BDX has been more active in the news (13 items in the past 4 weeks vs 9 for TMO).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $57.93B
- $255.19B
- 1M return
- +9.48%
- -0.77%
- 1Y return
- +42.82%
- +20.26%
- Industry
- Medical/Dental Instruments
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 13
- 9
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest BDX
- BD Marks 85 Years of Essential Medical Device Manufacturing in Glen Falls, NY
- BD Named to TIME's 2027 List of America's Top Manufacturers
- Director Huffines Robert Luther was granted 158 units of Rights to Common Stock Under BD Deferred Compensation Plan (SEC Form 4)
- Director Byington Carrie L was granted 79 units of Rights to Common Stock Under 1996 Directors Deferral Plan (SEC Form 4)
- BD to Host Investor Day on December 10, 2026
- Chairman, CEO and President Polen Thomas E Jr exercised 20,239 shares at a strike of $178.94, returned $3,621,660 worth of shares to the company (17,246 units at $210.00) and sold $628,530 worth of shares (2,993 units at $210.00) as part of a pre-agreed trading plan (SEC Form 4)
- Becton Dickinson upgraded by Wells Fargo with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
- BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
Latest TMO
- President & COO Pettiti Gianluca sold $2,898,969 worth of shares (4,133 units at $701.42) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 2% to 22,816 units (SEC Form 4)
- Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026
- Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
- Thermo Fisher Scientific Announces Quarterly Dividend
- SEC Form SCHEDULE 13G filed by Thermo Fisher Scientific Inc
- Director Sperling Scott M gifted 3,490 shares, decreasing direct ownership by 5% to 65,989 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $1,999,960 worth of shares (2,831 units at $706.45) (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- SEC Form 8-K filed by Thermo Fisher Scientific Inc